Revvity (RVTY) announced the launch of its Living Image Synergy AI multimodal analysis software for in vivo imaging researchers. The solution provides a platform with AI capabilities for seamless data analysis across optical, microCT, ultrasound, and other modalities-reducing data inconsistencies, streamlining workflows, increasing throughput, and enhancing reproducibility, all with the intention of accelerating scientific discovery.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVTY:
- Revvity price target lowered to $99 from $110 at BofA
- Revvity enters strategic collaboration with Profluent
- Revvity’s Strategic Positioning and Valuation: A Buy Rating Despite Market Reactions
- Revvity management to meet with KeyBanc
- Revvity’s Strategic Growth and Valuation Position: A Buy Rating Amidst Challenges